-
Mashup Score: 41
Approximately 8-10% of pancreatic ductal adenocarcinoma cases are KRAS wild-type. In a subset of these tumors, NRG1 gene fusions have been identified as targetable oncogenic drivers, a discovery that highlights the importance of deep molecular characterization …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies - 16 day(s) ago
PURPOSE Human epidermal growth factor receptor 2 (HER2) expression (protein immunohistochemistry [IHC] or gene amplification [copy-number variation, CNV]) predicts anti-HER2 therapy responsiveness, although recently it was shown that even low HER2-expressing breast cancers benefit from trastuzumab-deruxtecan. Little is known about HER2 transcriptomic (mRNA) expression, and comparisons between genomic, mRNA, and protein HER2 assays. METHODS HER2 status was evaluated using clinical-grade IHC (protein), quantitative reverse transcription polymerase chain reaction (mRNA), and next-generation sequencing (NGS; amplifications). RESULTS Multi-institutional HER2 testing was performed on 5,305 diverse cancers including non–small-cell lung (n = 1,175), breast (n = 1,040), and colon cancers (n = 566; N = 3,926 tested for CNV; N = 1,848, mRNA; N = 2,533, IHC). Overall, 4.1% (161/3,926) had NGS HER2 amplification; 33.3% (615/1,848) had mRNA overexpression; and 9.3% (236/2,533) were IHC-positive. In
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 67FDA approves an HDAC inhibitor for Duchenne muscular dystrophy - 17 day(s) ago
Nature Reviews Drug Discovery – Discover the world’s best science and medicine | Nature.com
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71Cancer Care in the Era of AI - 1 month(s) ago
This JAMA Oncology Patient Page explains artifical intelligence and what patients should know about how it can be used in oncology.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 105If it’s a target, it’s a pan-cancer target: Tissue is not the issue - 1 month(s) ago
Historically, cancer has been classified and treated on the basis of its organ of origin (e.g., breast or colon or lung cancer), which is determined by light microscopy. However, light microscopy does not uncover the factors that drive tumor formation and progression. Understanding tumor drivers requires molecular technology, which has fortunately advanced at a remarkable rate over the last two decades. As a result, there are now multiple tissue-agnostic Food and Drug Administration (FDA) approvals for patients with cancer (Fig.
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
AbstractPurpose:. Increased glucocorticoid receptor (GR) signaling is a proposed compensatory mechanism of resistance to androgen receptor (AR) inhibition in metastatic castration-resistant prostate cancer (mCRPC). ORIC-101 is a potent and selective orally-bioavailable GR antagonist.Patients and Methods:. Safety, pharmacokinetic/pharmacodynamic, and antitumor activity of ORIC-101 in combination with enzalutamide were studied in patients with mCRPC progressing on enzalutamide. ORIC-101 doses ranging from 80 to 240 mg once daily were tested in combination with enzalutamide 160 mg once daily. Pharmacokinetics/pharmacodynamics was assessed after a single dose and at steady state. Disease control rate (DCR) at 12 weeks was evaluated at the recommended phase 2 dose (RP2D).Results:. A total of 41 patients were enrolled. There were no dose-limiting toxicities and the RP2D was selected as 240 mg of ORIC-101 and 160 mg of enzalutamide daily. At the RP2D, the most common treatment-related adverse
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2About Workshop | vailworkshop.org - 2 month(s) ago
An intensive workshop in the essentials of effective clinical trial designs of therapeutic interventions in the treatment of cancer for clinical fellow and junior faculty clinical researchers in all oncology subspecialties, including radiation and surgical oncology and radiology. Affectionately known as the “Vail” Workshop due to its history in Vail, CO, the 2024 Workshop will be in a new location! The 2024 Workshop will be held in sunny La Jolla, California. The new location represents a less travel
Source: vailworkshop.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 292024 Patient Education Ambassadors Program | CancerGRACE - 2 month(s) ago
Applications are now open to oncology fellows and finishing fellows Program Information Form and Application
Source: cancergrace.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Conquer Cancer Announces 2024 Genitourinary Cancers Symposium Merit Awards | Conquer Cancer, the ASCO Foundation - 3 month(s) ago
ALEXANDRIA, Va. — Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipients of its 2024 Genitourinary Cancers Symposium Merit Awards. These distinguished awards recognize first authors on top-ranking abstracts selected for presentation at the ASCO Genitourinary Cancers Symposium, January 25–27, 2024, in San Francisco, California. The following 32 oncology professionals are recognized for their respective field and research advancements within the cancer care community: Oluseyi
Source: www.conquer.orgCategories: General Medicine News, Hem/OncsTweet
Who did it better😇☺️?! Comparing and contrasting Figures 1 from NRG1 papers from 2020 @CCR_AACR & 2024 @BMCMedicine from our paper! Honestly, I love the tactfulness & clarity! https://t.co/Ehhyg4lP5m vs. https://t.co/OkjDZEkaP5 😁 @Dr_R_Kurzrock, what do you think? https://t.co/jD9B2bxbEd